More on VERA
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $29.05 |
|
|||
| Open | $28.75 | ||||
| 52 Wk High | $1.18 | ||||
| 52 Wk Low | $0.36 | ||||
| Day High | $29.44 | ||||
| Day Low | $27.46 | ||||
| P/E | 466.50 | ||||
| EPS | $0.06 | ||||
| Volume | 1,982,083 | ||||
- Vera Therapeutics (VERA) Reiterated at Overweight by Cantor Fitzgerald
- Vera Therapeutics ORIGIN 3 trial meets all endpoints for IgAN drug
- Vera Therapeutics Announces Positive ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Presented at ASN Kidney Week 2026 and Published in the New England Journal of M
- Vera Therapeutics to Host ASN Kidney Week Investor Webcast and Third Quarter 2026 Financial Results Conference Webcast
- Leerink Starts Vera Therapeutics (VERA) at Market Perform
- Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Vera Therapeutics to present ORIGIN 3 trial data at ASN Kidney Week
- Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN
- Form 4 Vera Therapeutics, Inc. For: Sep 15 Filed by: Fordyce Marshall
- TD Cowen Reiterates Buy Rating on Vera Therapeutics (VERA)
Entities mentioned with VERA
- FDA | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Earnings | View Related Stories »
- Cowen & Co | View Related Stories »
- JPMorgan | View Related Stories »
- 13G | View Related Stories »
- Show More...
